GRTS - Gritstone Oncology Inc Stock Price, Fair Value and News

$0.010.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GRTS Price Action

GRTS RSI Chart

GRTS Valuation

GRTS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GRTS Fundamentals

GRTS Revenue

GRTS Earnings

GRTS Profitability

GRTS Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	15.6M	14.6M	0	0
2023	15.2M	11.7M	10.2M	16.3M
2022	15.7M	18.3M	18.7M	19.9M
2021	42.5M	44.8M	46.5M	48.2M
2020	4.3M	3.6M	3.6M	4.0M
2019	2.4M	3.7M	4.6M	4.4M
2018	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Gritstone Oncology Inc

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

CEO	Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
WEBSITE	https://gritstonebio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	233